Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566884911> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2566884911 abstract "Objectives: The anti-diabetic drug, metformin, is an AMPK activator with anti-tumorigenic effects. Indirectly, metformin improves insulin resistance and decreases insulin and glucose levels. Directly, metformin activates AMPK, leading to inhibition of the mTOR pathway. Everolimus is a traditional mTOR inhibitor, and its common toxicities include hyperglycemia and insulin resistance. Thus, we compared the efficacy of metformin versus everolimus in a genetically engineered mouse model of serous ovarian cancer (OC) under obese and non-obese conditions. Methods: We utilized the K18-gT121+/-; p53fl/fl;Brca1fl/fl (KpB) OC mouse model. KpB mice were subjected to 60% calories derived from fat in a high fat diet (HFD) to mimic diet-induced obesity versus 10% calories from fat in a low fat diet (LFD). Mice were treated with placebo, metformin orally (200 mg/kg/day) or everolimus intraperitoneally (3 mg/kg/day) following tumor onset for 4 weeks (N = 8-10 mice/group). Tumor size and volume were recorded weekly. Immunohistochemical analysis was performed on the ovarian tumors after treatment with placebo, metformin or everolimus to assess for effects on proliferation, apoptosis and downstream targets of the mTOR pathway. Individual slides were digitized using the Aperio ScanScope (Aperio Technologies, Vista, CA), and digital images were analyzed using Aperio ImageScope software. Results: Metformin inhibited tumor growth in the KpB mice fed a LFD (non-obese) and a HFD (obese), after one month of treatment. In the mice fed a HFD, metformin decreased tumor growth by 60% compared to control animals. Tumor growth was only decreased by 32% in the mice fed a LFD. A comparison of the anti-tumorigenic effects of metformin in mice fed a LFD versus a HFD demonstrated that metformin was more efficacious in those mice on the HFD (p = 0.003). Everolimus inhibited tumor growth by 39% and 38% in mice fed a HFD versus LFD, respectively. As compared to placebo-treated mice, metformin and everolimus decreased Ki-67, a marker of cell proliferation, and increased caspase-3, a marker of apoptosis, in the ovarian tumors from obese and non-obese KpB mice. In addition, metformin increased phosphorylation of AMPK, and both metformin and everolimus decreased phosphorylation of S6, a downstream target of the mTOR pathway. Conclusions: Metformin, an AMPK activator, was found to be more efficacious in the inhibition of ovarian tumor growth in the obese versus non-obese KpB mice, suggesting that obesity may be a biomarker for response to this agent. In contrast, everolimus, a mTOR inhibitor, was found to be equally efficacious in obese and non-obese mice. Further studies are underway to assess the potential differential effects of an AMPK activator versus a mTOR inhibitor on the interrelationship between the metabolic milieu and ovarian tumor growth. Citation Format: Weiya Z. Wysham, Yan Zhang, Hallum K. Dickens, Kimberly M. Malloy, Xiaoyun Han, Hui Guo, Paola A. Gehrig, Chunxiao Zhou, Victoria L. Bae-Jump. Differential efficacy of metformin versus everolimus in the setting of obesity in a mouse model of serous ovarian cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2305. doi:10.1158/1538-7445.AM2015-2305" @default.
- W2566884911 created "2017-01-06" @default.
- W2566884911 creator A5007239313 @default.
- W2566884911 creator A5007925500 @default.
- W2566884911 creator A5040452414 @default.
- W2566884911 creator A5063523041 @default.
- W2566884911 creator A5068522544 @default.
- W2566884911 creator A5077703334 @default.
- W2566884911 creator A5084844090 @default.
- W2566884911 creator A5086664284 @default.
- W2566884911 creator A5090707434 @default.
- W2566884911 date "2015-08-01" @default.
- W2566884911 modified "2023-10-15" @default.
- W2566884911 title "Abstract 2305: Differential efficacy of metformin versus everolimus in the setting of obesity in a mouse model of serous ovarian cancer" @default.
- W2566884911 doi "https://doi.org/10.1158/1538-7445.am2015-2305" @default.
- W2566884911 hasPublicationYear "2015" @default.
- W2566884911 type Work @default.
- W2566884911 sameAs 2566884911 @default.
- W2566884911 citedByCount "0" @default.
- W2566884911 crossrefType "proceedings-article" @default.
- W2566884911 hasAuthorship W2566884911A5007239313 @default.
- W2566884911 hasAuthorship W2566884911A5007925500 @default.
- W2566884911 hasAuthorship W2566884911A5040452414 @default.
- W2566884911 hasAuthorship W2566884911A5063523041 @default.
- W2566884911 hasAuthorship W2566884911A5068522544 @default.
- W2566884911 hasAuthorship W2566884911A5077703334 @default.
- W2566884911 hasAuthorship W2566884911A5084844090 @default.
- W2566884911 hasAuthorship W2566884911A5086664284 @default.
- W2566884911 hasAuthorship W2566884911A5090707434 @default.
- W2566884911 hasConcept C126322002 @default.
- W2566884911 hasConcept C134018914 @default.
- W2566884911 hasConcept C181199279 @default.
- W2566884911 hasConcept C190283241 @default.
- W2566884911 hasConcept C2776782570 @default.
- W2566884911 hasConcept C2777391703 @default.
- W2566884911 hasConcept C2779699572 @default.
- W2566884911 hasConcept C2780124434 @default.
- W2566884911 hasConcept C2780323712 @default.
- W2566884911 hasConcept C55493867 @default.
- W2566884911 hasConcept C555293320 @default.
- W2566884911 hasConcept C71924100 @default.
- W2566884911 hasConcept C86554907 @default.
- W2566884911 hasConcept C86803240 @default.
- W2566884911 hasConcept C97029542 @default.
- W2566884911 hasConceptScore W2566884911C126322002 @default.
- W2566884911 hasConceptScore W2566884911C134018914 @default.
- W2566884911 hasConceptScore W2566884911C181199279 @default.
- W2566884911 hasConceptScore W2566884911C190283241 @default.
- W2566884911 hasConceptScore W2566884911C2776782570 @default.
- W2566884911 hasConceptScore W2566884911C2777391703 @default.
- W2566884911 hasConceptScore W2566884911C2779699572 @default.
- W2566884911 hasConceptScore W2566884911C2780124434 @default.
- W2566884911 hasConceptScore W2566884911C2780323712 @default.
- W2566884911 hasConceptScore W2566884911C55493867 @default.
- W2566884911 hasConceptScore W2566884911C555293320 @default.
- W2566884911 hasConceptScore W2566884911C71924100 @default.
- W2566884911 hasConceptScore W2566884911C86554907 @default.
- W2566884911 hasConceptScore W2566884911C86803240 @default.
- W2566884911 hasConceptScore W2566884911C97029542 @default.
- W2566884911 hasLocation W25668849111 @default.
- W2566884911 hasOpenAccess W2566884911 @default.
- W2566884911 hasPrimaryLocation W25668849111 @default.
- W2566884911 hasRelatedWork W1487922930 @default.
- W2566884911 hasRelatedWork W1976890109 @default.
- W2566884911 hasRelatedWork W1981477038 @default.
- W2566884911 hasRelatedWork W2000376927 @default.
- W2566884911 hasRelatedWork W2008616193 @default.
- W2566884911 hasRelatedWork W2028263523 @default.
- W2566884911 hasRelatedWork W2050865113 @default.
- W2566884911 hasRelatedWork W2060536703 @default.
- W2566884911 hasRelatedWork W2066032552 @default.
- W2566884911 hasRelatedWork W2089256006 @default.
- W2566884911 hasRelatedWork W2325583904 @default.
- W2566884911 hasRelatedWork W2381104591 @default.
- W2566884911 hasRelatedWork W2478271681 @default.
- W2566884911 hasRelatedWork W2741410819 @default.
- W2566884911 hasRelatedWork W2954093073 @default.
- W2566884911 hasRelatedWork W2955566008 @default.
- W2566884911 hasRelatedWork W3048374256 @default.
- W2566884911 hasRelatedWork W3115092737 @default.
- W2566884911 hasRelatedWork W3120474328 @default.
- W2566884911 hasRelatedWork W3205349619 @default.
- W2566884911 isParatext "false" @default.
- W2566884911 isRetracted "false" @default.
- W2566884911 magId "2566884911" @default.
- W2566884911 workType "article" @default.